...U.S. and Canadian rights returned $8M up front; $4M upon closing of Santhera's acquisition of Juvantia Pharma Ltd....

...for the adrenergic receptor alpha 2 (ADRA2) antagonist, which it gained through its acquisition of Juvantia Pharma Ltd....

...Santhera completed its previously announced acquisition of Juvantia in a stock deal valued at CHF3.3 million...
...from Juvantia (see BioCentury, Aug. 24 & Aug. 31). Biovail Corp. (TSX:BVF; NYSE:BVF), Mississauga, Ontario Juvantia Pharma Ltd....

...Catena idebenone (SNT-MC17) in Phase III testing to treat Friedreich's ataxia, fipamezole (JP-1730) partnered with Juvantia Pharma Ltd....

...board. Quick flip The reason Santhera Pharmaceutical Holdings AG (SIX:SANN) exercised its option to buy Juvantia Pharma Ltd....
...partnership with Biovail Corp. (TSX:BVF; NYSE:BVF) worth as much as $212 million plus royalties for Juvantia's...
...Santhera disclosed that it had exercised its option from a July 2006 partnership to acquire Juvantia...

...dyskinesia in patients with Parkinson's disease. Santhera will gain fipamezole through its pending acquisition of Juvantia Pharma Ltd....
...pay Santhera $8 million up front and a further $4 million upon closing of the Juvantia...

...dyskinesia in patients with Parkinson's disease. Santhera will gain fipamezole through its pending acquisition of Juvantia Pharma Ltd....
...pay Santhera US$8 million up front and a further US$4 million upon closing of the Juvantia...

...retail investors drive its share price. Unprotected on downside Investors in virtual Finnish company Oy Juvantia Pharma Ltd....
...week exercised its option to buy the company. The deal gives Santhera full rights to Juvantia's...
...of shares would only have been worth CHF9.5 million ($8.8 million, €5.5 million). By contrast, Juvantia's...

...Santhera exercised an option to acquire Juvantia in a stock deal valued at CHF2.9 million ($2.7...
...Santhera gained the option under a 2006 deal in which the companies partnered to develop Juvantia's...
...patients. Santhera will now have full rights to the compound (see BioCentury, Sept. 11, 2006). Juvantia Pharma Ltd....

...in Phase II testing to treat dyskinesia in Parkinson's disease patients. Fipamezole is partnered with Juvantia Pharma Ltd....